Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5014287 | 0.84 | KDM4E (0.52) | THRB | |
| SCHEMBL4887665 | 0.82 | RAB9A (0.42) | POLBMAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4363143 | 0.82 | POLB (0.51) | POLBMAPTSMN1; SMN2THRBKMT2A | |
| SCHEMBL5226577 | 0.82 | C1R (0.45) | POLBMAPTSMN1; SMN2THRBALDH1A1 | |
| SCHEMBL979145 | 0.78 | KDM4E (0.65) | — | |
| SCHEMBL5545407 | 0.76 | NPC1 (0.50) | POLBSMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL4888378 | 0.76 | RAB9A (0.62) | LMNA | |
| SCHEMBL1436051 | 0.76 | PPARA (0.51) | MAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6607539 | 0.75 | MEN1 (0.42) | POLBMAPTSMN1; SMN2THRBKMT2A | |
| SCHEMBL3530493 | 0.74 | RAB9A (0.53) | POLBSMN1; SMN2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446127-B2 | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders | SK HOLDINGS CO, LTD. (KR) | 2008-11-04 | — | — | US | disclosed |
| EP-1660490-A1 | CHROMAN CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | SK Corporation (KR) | 2006-05-31 | — | — | EP | disclosed |
| US-20050107371-A1 | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2005-05-19 | — | — | US | disclosed |
| WO-2005021540-A1 | CHROMAN CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | SK CORPORATION (KR) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107371-A1 | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders | GPR119, CEL, ACACA | POLB 3872/4885MAPT 4593/4885SMN1; SMN2 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.